stockrowRevolution Medicines, Inc.
RVMD Healthcare Biotechnology
Revolution Medicines, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $11.6 million, down 67.3% from fiscal 2022.
- Revenue
- +1,188.7%
- EPS
- −18.0%
- Free cash flow
- −99.1%
- Total debt
- +322.7%
Quarter to September 2026, against a year earlier
Follow RVMD
Alert me
Revolution Medicines, Inc. (RVMD) EBITDA
Revolution Medicines, Inc.'s EBITDA for fiscal 2025 was −$1.2B, compared with −$722.3M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$1.6B. Over the past ten years it has ranged from −$1.2B (fiscal 2025) to −$29.9M (fiscal 2017) — the current reading is the lowest in ten years. EBITDA has fallen for 8 consecutive fiscal years. Revolution Medicines, Inc. ranks 593rd of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | −$1.2B | — |
| FY2024 | −$722.3M | — |
| FY2023 | −$500.1M | — |
| FY2022 | −$251.7M | — |
| FY2021 | −$177.7M | — |
| FY2020 | −$103.2M | — |
| FY2019 | −$51.2M | — |
| FY2018 | −$38.6M | — |
| FY2017 | −$29.9M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | −$505.0M | — |
| Mar 2026 | −$443.9M | — |
| Dec 2025 | −$361.5M | — |
| Sep 2025 | −$316.6M | — |
| 26 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| ARGX argenex SE compare | $1.7B |
| RPRX Royalty Pharma PLC compare | $1.5B |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | $1.4B |
| GMAB Genmab A/S Sponsored ADR compare | $1.2B |
| INCY Incyte Corporation compare | $724.9M |
| INSM Insmed, Inc. compare | −$531.4M |
| ROIV Roivant Sciences Ltd. compare | −$593.3M |
| BNTX BioNTech SE Sponsored ADR compare | −$1.1B |
| RVMD Revolution Medicines, Inc. | −$1.6B |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on RVMD
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement